Effects of Hydroxyurea on F ‐cells in Sickle Cell Disease and Potential Impact of a Second Fetal Globin Inducer
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 21, 2016 Category: Hematology Authors: Yan Dai, Jose Sangerman, Mehdi Nouraie, Aidan D. Faller, Patricia Oneal, Angela Rock, Oluwakemi Owoyemi, Xiaomei Niu, Sergei. Nekhai, Dashmeet Maharaj, Shauiying Cui, Robert Taylor, Martin Steinberg, Susan Perrine Tags: Correspondence Source Type: research

Mononucleosis ‐induced pseudo neutropenia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 20, 2016 Category: Hematology Authors: Michael Loudin, Thomas Deloughery, Joseph Shatzel Tags: Images in Hematology Source Type: research

Hydroxyurea Effectiveness in Children and Adolescents with Sickle Cell Anemia: A Large Retrospective, Population ‐Based Cohort
Abstract The clinical efficacy of hydroxyurea in patients with sickle cell anemia (SCA) has been well established. However, data about its clinical effectiveness in practice is limited. We evaluated the clinical effectiveness of hydroxyurea in a large pediatric population using a retrospective cohort, pre‐post treatment study design to control for disease severity selection bias. The cohort included children with SCA (SS, Sβ0thalassemia) who received care at Children's Healthcare of Atlanta (CHOA) and who initiated hydroxyurea in 2009‐2011. Children on chronic transfusions, or children with inadequate follow up da...
Source: American Journal of Hematology - October 20, 2016 Category: Hematology Authors: Maa ‐Ohui Quarmyne, Wei Dong, Rodney Theodore, Sonia Anand, Vaughn Barry, Olufolake Adisa, Iris D. Buchanan, James Bost, Robert C. Brown, Clinton H. Joiner, Peter A. Lane Tags: Research Article Source Type: research

Clinical Pathways in Chronic lymphocytic Leukemia: Challenges and Solutions
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 19, 2016 Category: Hematology Authors: Chadi Nabhan, Anthony R. Mato, Bruce A. Feinberg Tags: Commentary Source Type: research

Treatment of Central Venous Catheter ‐Associated Deep Venous Thrombosis in Cancer Patients with Rivaroxaban
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 19, 2016 Category: Hematology Authors: Eva S Laube, Simon Mantha, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff Tags: Correspondence Source Type: research

Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management
Disease overview:Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extra‐cutaneous organs. Diagnosis: The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC expression of CD25 and/or CD2, and presence of KITD816V. Risk stratification: The 2008 World Health Organization (WHO) classification of SM has been shown to be prognostically relevant. Classification of SM patients into indolent (SM), aggressive SM (ASM), SM associated with a clonal no...
Source: American Journal of Hematology - October 19, 2016 Category: Hematology Authors: Animesh Pardanani Tags: CME Information: Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management Source Type: research

2017 Clinical trials update in new treatments of β‐thalassemia
The underlying basis of β‐thalassemia pathology is the diminished β‐globin synthesis leading to α‐globin accumulation and premature apoptotic destruction of erythroblasts, causing oxidative stress‐induced ineffective erythropoiesis, bone marrow hyperplasia, splenomegaly, and increased intestinal iron absorption with progressive iron overload. Better understanding of the molecular mechanisms underlying this disease led to the recognition of new targets with potential therapeutic utility. Agents such as JAK2 inhibitors and TGF‐β ligand traps that reduce the ineffective erythropoiesis process ar...
Source: American Journal of Hematology - October 19, 2016 Category: Hematology Authors: Alexandros Makis, Eleftheria Hatzimichael, Ioannis Papassotiriou, Ersi Voskaridou Tags: Updates in Clinical Trials for Hematological Diseases Source Type: research

Issue Information – Table of Contents
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 19, 2016 Category: Hematology Tags: Issue Information – Table of Contents Source Type: research

Concurrent STAT3, DNMT3A and TET2 mutations in T ‐LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 18, 2016 Category: Hematology Authors: Philipp W. Raess, Michael J. Cascio, Guang Fan, Richard Press, Brian J. Druker, Diana Brewer, Stephen E. Spurgeon Tags: Correspondence Source Type: research

Atypical hemolytic uremic syndrome associated with Capnocytophaga canimorsus
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 13, 2016 Category: Hematology Authors: Kelsey A. Sokol, Rajwanth R. Veluswamy, Brittney S. Zimmerman, Sri Lekha Tummalapalli, Kevin Troy Tags: Images in Hematology Source Type: research

The use of biomarkers to describe plasma ‐, red cell‐ and blood volume from a simple blood test
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - October 12, 2016 Category: Hematology Authors: Louisa M. Lobigs, Pierre ‐Edouard Sottas, Pitre C. Bourdon, Zoran Nikolovski, Mohamed El‐Gingo, Evdokia Varamenti, Peter Peeling, Brian Dawson, Yorck O. Schumacher Tags: Research Article Source Type: research

Refractory Hairy Cell Leukemia ‐Variant
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 10, 2016 Category: Hematology Authors: Zhihong Hu, Yi Sun, Wei Wang, L. Jeffrey Medeiros, Rashmi Kanagal ‐Shamanna Tags: Images in Hematology Source Type: research

Molecular Testing for JAK2, MPL, and CALR in Myeloproliferative Neoplasms
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - October 10, 2016 Category: Hematology Authors: Daniel Xia, Robert P. Hasserjian Tags: Test of the Month Source Type: research

Chronic Granulomatous Disease: Clinical, Functional, Molecular and Genetic Studies. The Israeli Experience with 84 patients
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - October 3, 2016 Category: Hematology Authors: Baruch Wolach, Ronit Gavrieli, Martin de Boer, Karin van Leeuwen, Sivan Berger ‐Achituv, Tal Stauber, Josef Ben Ari, Menachem Rottem, Yechiel Schlesinger, Galia Grisaru‐Soen, Omar Abuzaitoun, Nufar Marcus, Ben Zion Garty, Arnon Broides, Jakov Levy, Po Tags: Research Article Source Type: research

Hereditary Persistence of Fetal Hemoglobin in two patients with KLF1 haploinsufficiency due to 19p13.2 –p13.12/13 deletion
(Source: American Journal of Hematology)
Source: American Journal of Hematology - October 3, 2016 Category: Hematology Authors: Abdelhafid Natiq, Philippe A. Lysy, Nynke Gillemans, Rianne Schaap, Abdelaziz Sefiani, Saaid Amzazi, Siham Chafai El ‐Alaoui, Ileana Cantú, Bella Banjanin, Kirsten van Lom, Cornelis L. Harteveld, Sjaak Philipsen Tags: Correspondence Source Type: research

2017 Clinical trials update: Innovations in hemophilia therapy
A surge in therapeutic clinical trials over recent years is paving the way for transformative treatment options for patients with hemophilia. The introduction of recombinant factor concentrates in the early 1990s facilitated the use of prophylactic replacement as standard care for hemophilia rather than on‐demand treatment. This has revolutionized health outcomes for hemophilia patients, enabling participation in physical activities and reducing debilitating, chronic joint damage. Challenges of prophylactic factor infusion include the frequency of infusions needed to maintain factor levels greater than 1%, patient adhere...
Source: American Journal of Hematology - October 2, 2016 Category: Hematology Authors: Jan Hartmann, Stacy E. Croteau Tags: Updates in Clinical Trials for Hematological Diseases Source Type: research

Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype
Current definitions of acute chest syndrome (ACS) in sickle cell anemia (SCA) do not account for rapid progression of respiratory compromise. In this two‐center retrospective cohort study, we tested the hypothesis that in children and adults with ACS and respiratory failure (≤24 hours after onset of respiratory symptoms) have a distinct ACS phenotype associated with multiorgan failure when compared to those with ACS that have a more subacute and protracted course. We identified 173 individuals (97 children
Source: American Journal of Hematology - October 2, 2016 Category: Hematology Authors: Shruti Chaturvedi, Djamila L. Ghafuri, Jeffrey Glassberg, Adetola A. Kassim, Mark Rodeghier, Michael R. DeBaun Tags: Research Article Source Type: research

A Randomized and Double ‐Blind Controlled Trial Evaluating the Safety and Efficacy of Rituximab for Warm Auto‐Immune Hemolytic Anemia in Adults (the RAIHA study)
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - October 2, 2016 Category: Hematology Authors: Marc Michel, Louis Terriou, Francoise Roudot ‐Thoraval, Mohamed Hamidou, Mikael Ebbo, Guillaume Le Guenno, Lionel Galicier, Sylvain Audia, Bruno Royer, Anne Sophie Morin, Jean Marie Michot, Arnaud Jaccard, Laurent Frenzel, Mehdi Khellaf, Bertrand Godeau Tags: Research Article Source Type: research

DNMT3A Mutations are Associated with Inferior Overall and Leukemia ‐free Survival in Chronic Myelomonocytic Leukemia
Abstract DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n=261). DNMT3A mutations were seen in 6% (n=16); 56% (n=9) male, with a median age of 64 years. Eighty‐one % of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes. Five (31%) patients had an abnormal karyotype whereas concurrent gene mutations (SF3B1/SRSF2/U2AF1‐56%, TET2‐...
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: Mrinal M. Patnaik, Daniela Barraco, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Ayalew Tefferi Tags: Research Article Source Type: research

Clinical characteristics of Philadelphia positive T ‐cell lymphoid leukemias – (de novo and blast phase CML)
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: Preetesh Jain, Hagop Kantarjian, Elias Jabbour, Rashmi Kanagal ‐Shamanna, Keyur Patel, Sherry Pierce, Guillermo Garcia‐Manero, Gautam Borthakur, Farhad Ravandi, Susan O'Brien, Jorge Cortes Tags: Correspondence Source Type: research

Red Cell Survival and NO Scavenging in Sickle Cell Disease
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: H. Franklin Bunn Tags: Commentary Source Type: research

Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B ‐cell Acute Lymphoblastic Leukemia
We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B‐ALL age 55 years and older and explored prognostic factors associated with long‐term outcomes. Methods: Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55‐72) with B‐ALL with disease status in CR1 (71%),>CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001‐2012 using mostly unrelated donor (59%) or HLA‐matched sibling (32%). Among patients with available cytogenetic data, the Philadelphia chromosome (Ph+) was present ...
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: Ashley Rosko, Hai ‐Lin Wang, Marcos de Lima, Brenda Sandmaier, H. Jean Khoury, Andrew Artz, Johnathan Brammer, Christopher Bredeson, Sherif Farag, Mohamed Kharfan‐Dabaja, Hillard M. Lazarus, David I. Marks, Rodrigo Martino Bufarull, Joseph McGuirk, Mo Tags: Research Article Source Type: research

Risk Factors for Infections In Myelofibrosis: Role of Disease Status and Treatment. A multicenter study of 507 patients
Abstract Although infectious complications represent a relevant cause of morbidity and mortality in patients with myelofibrosis (MF), little is known about their incidence, outcome and risk factors. We retrospectively evaluated a cohort of 507 MF patients, diagnosed between 1980 and 2014 in five Italian hematology centers, to define the epidemiology of infections and describe the impact of ruxolitinib (RUX) treatment. Overall, 112 patients (22%) experienced 160 infectious events (grade 3‐4, 45%) for an incidence rate of 3.9% per patient‐year. Infections were mainly bacterial (78%) and involving the respiratory tract (5...
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: Nicola Polverelli, Massimo Breccia, Giulia Benevolo, Bruno Martino, Alessia Tieghi, Roberto Latagliata, Elena Sabattini, Mara Riminucci, Laura Godio, Lucia Catani, Maura Nicolosi, Margherita Perricone, Daria Sollazzo, Gioia Colafigli, Anna Campana, France Tags: Research Article Source Type: research

CD38, BCL ‐2, PD‐1 and PD‐1L expression in nodal peripheral T‐cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies?
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 30, 2016 Category: Hematology Authors: Francesco Zaja, Valentina Tabanelli, Claudio Agostinelli, Angelica Calleri, Annalisa Chiappella, Marzia Varettoni, Pier Luigi Zinzani, Stefano Volpetti, Elena Sabattini, Renato Fanin, Stefano Aldo Pileri Tags: Correspondence Source Type: research

Erythrocyte adenosine deaminase levels are elevated in Diamond Blackfan anemia but not in the 5q − syndrome
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 29, 2016 Category: Hematology Authors: Anupama Narla, Natalie L. Davis, Corinne Lavasseur, Carolyn Wong, Bertil Glader Tags: Correspondence Source Type: research

Thiotepa ‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia ‐ a survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 28, 2016 Category: Hematology Authors: Sandra Eder, Eric Beohou, Myriam Labopin, Jaime Sanz, J ürgen Finke, William Arcese, Reuven Or, Francesca Bonifazi, Mahmoud Aljurf, Gerard Socié, Jakob Passweg, Sebastian Giebel, Mohamad Mohty, Arnon Nagler Tags: Research Article Source Type: research

PET ‐positive lymphadenopathy in CLL – Not always Richter transformation
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 26, 2016 Category: Hematology Authors: Naveen Pemmaraju, Preetesh Jain, L. Jeffrey Medeiros, Jeffrey L. Jorgenson, Nitin Jain, Jason Willis, Dimitrios P. Kontoyiannis, Zeev Estrov, William Wierda Tags: Images in Hematology Source Type: research

Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 26, 2016 Category: Hematology Authors: Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Jorge Cortes, Gautam Borthakur, LaKiesha DeBose, Zhihong Zeng, Heather Schneider, Naveen Pemmaraju, Guillermo Garcia ‐Manero, Steven Kornblau, William Wierda, Jan Burger, Courtney D. Tags: Research Article Source Type: research

Fludarabine and Cytarabine versus High ‐dose Cytarabine in Consolidation Treatment of t(8; 21) Acute Myeloid Leukemia: a prospective, randomized study
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 26, 2016 Category: Hematology Authors: Ruiqi Li, Xiaoxia Hu, Libing Wang, Hui Cheng, Shuqing Lv, Weiping Zhang, Jianmin Wang, Jianmin Yang, Xianmin Song Tags: Research Article Source Type: research

Circulating lymphoma cells in intravascular large B ‐cell lymphoma
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 23, 2016 Category: Hematology Authors: Nicholas J. Fordham, Simon O'Connor, Simon Stern, Veselka Nikolova, Barbara J. Bain Tags: Morphology Update Source Type: research

Reply to McCulley et al., reports to FDA of fatal anaphylaxis associated with intravenous iron products
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 22, 2016 Category: Hematology Authors: Michael Auerbach, John Adamson Tags: Correspondence Source Type: research

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid ‐directed monoclonal antibody
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 21, 2016 Category: Hematology Authors: Morie A. Gertz, Heather J. Landau, Brendan M. Weiss Tags: Correspondence Source Type: research

Cutaneous B ‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management
Disease overviewApproximately one‐fourth of cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). DiagnosisDiagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with se...
Source: American Journal of Hematology - September 20, 2016 Category: Hematology Authors: Ryan A. Wilcox Tags: CME Information: Cutaneous B ‐cell lymphomas: 2016 update on diagnosis, risk‐stratification, and management Source Type: research

Issue Information – Table of Contents
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 20, 2016 Category: Hematology Tags: Issue Information – Table of Contents Source Type: research

Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia
Abstract Hemolysis is a key feature of sickle cell anemia (HbSS). Direct quantitation of hemolysis could be used as an objective outcome in clinical trials of new therapeutics for HbSS and would also enable better human studies of the pathogenesis of complications of HbSS that are ostensibly hemolysis‐related, such as pulmonary hypertension. However, contemporary human studies in HbSS have used only surrogate markers of hemolysis rather than direct measurements of RBC survival. We directly quantified hemolysis in HbSS by measuring survival of an age cohort of RBCs labeled with a stable isotope, administered orally as 15N...
Source: American Journal of Hematology - September 19, 2016 Category: Hematology Authors: Charles T. Quinn, Eric P. Smith, Shahriar Arbabi, Paramjit K. Khera, Christopher J. Lindsell, Omar Niss, Clinton H. Joiner, Robert S. Franco, Robert M. Cohen Tags: Research Article Source Type: research

A retrospective comparative outcome analysis following systemic therapy in Mycosis Fungoides and Sezary Syndrome
Conclusions: With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced‐stage disease. Therefore, clinical trial participation with novel agents should be encouraged. This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 19, 2016 Category: Hematology Authors: Walter Hanel, Robert Briski, Charles W. Ross, Thomas F. Anderson, Mark S. Kaminski, Alexandra C. Hristov, Ryan A Wilcox Tags: Research Article Source Type: research

Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML ( ≥60 Years) who Benefit from Intensive Post‐Induction Consolidation Therapy
Abstract Although it is generally appreciated that a subset of elderly patients with acute myeloid leukemia (AML) may benefit from intensive consolidation, little is known about variables predicting such benefit. We analysed 192 consecutive patients with de novo AML aged ≥60 years who were treated with intensive chemotherapy. One‐hundred‐fifteen patients (60%) achieved complete hematologic remission (CR). Among several parameters, the karyotype was the only independent variable predicting CR (p
Source: American Journal of Hematology - September 18, 2016 Category: Hematology Authors: Wolfgang R. Sperr, Otto Zach, Iris P öll, Susanne Herndlhofer, Paul Knoebl, Ansgar Weltermann, Berthold Streubel, Ulrich Jaeger, Michael Kundi, Peter Valent Tags: Research Article Source Type: research

Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non ‐comparative study
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 18, 2016 Category: Hematology Authors: Ygal Benhamou, Gilles Paintaud, Elie Azoulay, Pascale Poullin, Lionel Galicier, C éline Desvignes, Jean‐Luc Baudel, Julie Peltier, Jean‐Paul Mira, Frédéric Pène, Claire Presne, Samir Saheb, Christophe Deligny, Alexandra Rousseau, Frédéric Féger Tags: Research Article Source Type: research

Encapsulated relapsed flt3+AML (myeloid sarcoma) and hurthle cell adenoma presenting in composite: unlikely partners
(Source: American Journal of Hematology)
Source: American Journal of Hematology - September 18, 2016 Category: Hematology Authors: Fiona He, Kevin Ha, Zuzan Cayci, Maria Evasovich Swenson, Luiza Caramori, Khalid Amin, Michael A. Linden, Celalettin Ustun Tags: Correspondence Source Type: research

Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 14, 2016 Category: Hematology Authors: Jakob Werner Hansen, Maj Karoline Westman, Lene Dissing Sj ö, Lenonie Saft, Lasse Sommer Kristensen, Andreas Due Ørskov, Marianne Treppendahl, Mette Klarskov Andersen, Kirsten Grønbæk Tags: Research Article Source Type: research

Clonal Hematopoiesis in Patients with Dyskeratosis Congenita
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 12, 2016 Category: Hematology Authors: Nieves Perdigones, Juan C. Perin, Irene Schiano, Peter Nicholas, Jaclyn A. Biegel, Philip J. Mason, Daria V. Babushok, Monica Bessler Tags: Research Article Source Type: research

Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - September 12, 2016 Category: Hematology Authors: Emmanuel J Favaloro Tags: Test of the Month Source Type: research

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma
Deletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long‐term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence in situ hybridization (FISH) in CD138‐purified myeloma cells to identify prognostic factors for survival. Age>65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10–60% of plasma cells) del(17p) had longer progression‐free survival (PFS) than patients with del(17p) in&g...
Source: American Journal of Hematology - September 2, 2016 Category: Hematology Authors: Maximilian Merz, Thomas Hielscher, Anja Seckinger, Dirk Hose, Elias K. Mai, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jens Hillengass Tags: Research Article Source Type: research

Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Albertine E. Donker, Charlotte C. Schaap, Vera M.J. Novotny, Roel Smeets, Tessa M.A. Peters, Bert L. P. van den Heuvel, Martine F. Raphael, Anita W. Rijneveld, Inge M. Appel, Andre J. Vlot, A. Birgitta Versluijs, Michel van Gelder, Bernd Granzen, Mirian C Tags: Research Article Source Type: research

Safety and effectiveness of extended versus shortened iron dextran infusion time for the treatment of iron deficiency anemia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Sarah Deitering, Lisa Anslemo, Allison Burnett, Bernadette Jakeman Tags: Correspondence Source Type: research

Transcranial Doppler Re ‐screening of Subjects who Participated in STOP and STOP II
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Robert J. Adams, Dan T. Lackland, Lynette Brown, David Brown, Jenifer Voeks, Heather J. Fullerton, Julie Kanter, Janet L. Kwiatkowski Tags: Research Article Source Type: research

Striking dyserythropoiesis in a myelodysplastic syndrome
(Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Wenchee Siow, Philippa C. May, Ruby Haji, Ian Gabriel, Barbara J. Bain Tags: Morphology Update Source Type: research

Cold autoimmune hemolytic anemia secondary to atypical pneumonia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Maria Atta, Eimear T. Brannigan, Barbara J. Bain Tags: Morphology Update Source Type: research

Presence of B ‐cell precursors in bone marrow is a favorable independent prognostic factor for overall survival in patients with myelodysplastic syndromes
(Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Konradin Metze, Suiellen C. Reis ‐Alves, Irene G. H. Lorand‐Metze Tags: Correspondence Source Type: research

Phase II Trial of Nab ‐paclitaxel in Patients with Relapsed or Refractory Multiple Myeloma
(Source: American Journal of Hematology)
Source: American Journal of Hematology - August 31, 2016 Category: Hematology Authors: Tania Jain, Amylou C. Dueck, Heidi E. Kosiorek, Brenda F. Ginos, Angela Mayo, Craig B. Reeder, Marta Chesi, Joseph Mikhael, A. Keith Stewart, P. Leif Bergsagel, Rafael Fonseca Tags: Correspondence Source Type: research